Kyntra Bio, Inc. (KYNB) is a San Francisco–based, Nasdaq-listed biopharmaceutical company — formerly FibroGen — that has repositioned itself as a rare-disease developer built around roxadustat for anemia in lower-risk myelodysplastic syndromes, alongside royalty interests in EVRENZO outside the United States. On Tuesday the stock traded at $2.25, down $0.95 or 29.69% from the prior session's close of $3.20, extending a year-to-date collapse of more than 60%. The direction and magnitude of the decline are unambiguous: shares moved sharply lower. The reason is verified and fundamental — the company's third-quarter release, published after Monday's close, confirmed it is abandoning its prostate-cancer pipeline and now depends on a single asset whose pivotal trial is not yet funded.
The quarterly numbers themselves were mixed and largely secondary. Revenue from continuing operations was $1.76 million, up 64% year over year but slightly below consensus, while reported net income of $0.2 million — or $0.04 per share — was almost entirely the product of a $14.0 million debt-restructuring gain, not operations. The operating loss actually widened to $12.9 million from $5.4 million, with research and development costs rising to $8.3 million.
What drove the share price was the pipeline disclosure. Following a pre-specified interim analysis of the ongoing Phase 2 study of FG-3246, a CD46-targeting antibody-drug conjugate, the company concluded that preliminary efficacy did not clear the threshold required to continue. Enrollment is being closed, development is discontinued, and the paired FG-3180 imaging agent is being dropped as well, with the asset returning to its partner. Management expects the wind-down to save more than $20 million in operating expenses across 2027 and 2028 — a rational capital decision, but one that removes the program several 2026 analyst initiations were built around.
Kyntra Bio is now effectively a single-program story: roxadustat in lower-risk MDS with high transfusion burden, where the company points to a post-hoc slice of the MATTERHORN trial showing 36% transfusion independence versus 7% for placebo. The protocol is finalized and aligned with regulators, but initiation of the ~200-patient Phase 3 is planned for the first quarter of 2027 only "subject to the execution of either a strategic partnership or an external capital raise."
With $44.1 million in cash, investments and receivables, runway extends into 2028 largely because the trial has not begun. For a company now valued at roughly $9 million, that conditional clause reframes the equity as an option on a financing event, and investors repriced accordingly.
The sell-side reaction reinforced the move rather than causing it. HC Wainwright lowered its price target to $18 from $43 on Tuesday morning, keeping a constructive rating but marking down the value of a company with one remaining program. Published consensus targets near $35 are now stale relics of a two-program model and should be read with caution.
This was not a sector event. The major biotech ETF XBI slipped about 0.2%, the small-cap IWM eased 0.2%, and the QQQ was similarly quiet — leaving a near-30% single-stock decline almost entirely idiosyncratic.
Participation was far above normal. Roughly 62,000 shares traded in the first 30 minutes against a 20-day average near 25,000, with the gap-down open near $2.33 and an intraday range of $2.02 to $2.39. Technically, the stock gapped below every meaningful reference point: the 50-day moving average near $5.73 and the 200-day near $6.84, both now far overhead, with the shares printing a new 52-week low under the prior $2.61 floor after an already deeply oversold reading. Such thin float — about 3.6 million shares — amplifies gaps of this kind.
The scale runs from 0, meaning no meaningful news and a move typical for the stock, to 100, meaning transformative news and an extreme, rare price move. Kyntra Bio's score is 86 out of 100.
The news was genuinely major: a clinical program failure that eliminates a lead asset and leaves a funding-dependent Phase 3 as the sole value driver, for a company of this size. The price reaction was equally unusual. Tuesday's 29.69% decline was about ten times the stock's average absolute daily move of roughly 3% over the prior 69 sessions, and no session in that window produced a comparable swing — the largest was under 10%. Strong news and a rare move combine into a high score.
Attention shifts to financing. Any announcement of a strategic partner or capital raise for the roxadustat Phase 3 would be the pivotal event, and the terms will determine how much value accrues to existing holders. The company has guided to a first-quarter 2027 trial start, with an interim futility analysis not expected before the second half of 2028 and primary analysis in 2030 — a long timeline for a micro-cap. Investors will also monitor quarterly cash burn, royalty receipts from Astellas, and any update on Nasdaq continued-listing compliance, given the shares' sub-$1 billion valuation metrics and sustained decline. Sector sentiment toward unprofitable single-asset biotechs remains a swing factor.
Tickeron's Trending AI Robots page is a curated leaderboard of the platform's strongest automated strategies under present market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and only the top performers are surfaced here. Bots differ by strategy style, timeframe, performance metrics and the symbols they trade, so the list rotates as market conditions shift. For readers tracking volatile names like this one, it is a practical starting point for comparing live strategy performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where KYNB advanced for three days, in 227 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
KYNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYNB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for KYNB entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.501) is normal, around the industry mean (3.592). P/E Ratio (0.082) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (6.689) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. KYNB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology